Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers

Bradley A. Hancock, Yu Hsiang Chen, Jeffrey P. Solzak, Mufti N. Ahmad, David C. Wedge, Dumitru Brinza, Charles Scafe, James Veitch, Rajesh Gottimukkala, Walt Short, Rutuja V. Atale, Mircea Ivan, Sunil S. Badve, Bryan P. Schneider, Xiongbin Lu, Kathy D. Miller, Milan Radovich

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Background: Approximately two thirds of patients with localized triple-negative breast cancer (TNBC) harbor residual disease (RD) after neoadjuvant chemotherapy (NAC) and have a high risk-of-recurrence. Targeted therapeutic development for TNBC is of primary significance as no targeted therapies are clinically indicated for this aggressive subset. In view of this, we conducted a comprehensive molecular analysis and correlated molecular features of chemorefractory RD tumors with recurrence for the purpose of guiding downstream therapeutic development. Methods: We assembled DNA and RNA sequencing data from RD tumors as well as pre-operative biopsies, lymphocytic infiltrate, and survival data as part of a molecular correlative to a phase II post-neoadjuvant clinical trial. Matched somatic mutation, gene expression, and lymphocytic infiltrate were assessed before and after chemotherapy to understand how tumors evolve during chemotherapy. Kaplan-Meier survival analyses were conducted categorizing cancers with TP53 mutations by the degree of loss as well as by the copy number of a locus of 18q corresponding to the SMAD2, SMAD4, and SMAD7 genes. Results: Analysis of matched somatic genomes pre-/post-NAC revealed chaotic acquisition of copy gains and losses including amplification of prominent oncogenes. In contrast, significant gains in deleterious point mutations and insertion/deletions were not observed. No trends between clonal evolution and recurrence were identified. Gene expression data from paired biopsies revealed enrichment of actionable regulators of stem cell-like behavior and depletion of immune signaling, which was corroborated by total lymphocytic infiltrate, but was not associated with recurrence. Novel characterization of TP53 mutation revealed prognostically relevant subgroups, which were linked to MYC-driven transcriptional amplification. Finally, somatic gains in 18q were associated with poor prognosis, likely driven by putative upregulation of TGFß signaling through the signal transducer SMAD2. Conclusions: We conclude TNBCs are dynamic during chemotherapy, demonstrating complex plasticity in subclonal diversity, stem-like qualities, and immune depletion, but somatic alterations of TP53/MYC and TGFß signaling in RD samples are prominent drivers of recurrence, representing high-yield targets for additional interrogation.

Original languageEnglish (US)
Article number87
JournalBreast Cancer Research
Volume21
Issue number1
DOIs
StatePublished - Aug 5 2019

Keywords

  • Breast
  • Cancer
  • Chemoresistance
  • MYC
  • Recurrence
  • Relapse
  • SMAD2
  • TGF-beta
  • TP53
  • Triple-negative

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers'. Together they form a unique fingerprint.

  • Cite this

    Hancock, B. A., Chen, Y. H., Solzak, J. P., Ahmad, M. N., Wedge, D. C., Brinza, D., Scafe, C., Veitch, J., Gottimukkala, R., Short, W., Atale, R. V., Ivan, M., Badve, S. S., Schneider, B. P., Lu, X., Miller, K. D., & Radovich, M. (2019). Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers. Breast Cancer Research, 21(1), [87]. https://doi.org/10.1186/s13058-019-1171-7